Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1 promoter methylation predicts PARPi response in ovarian cancer: insights from the KOMET study

7 Aug 2025

Abstract excerpt

OBJECTIVES: PARP inhibitors (PARPi) have become the new standard maintenance treatment for patients with advanced homologous recombination deficiency (HRD) ovarian cancer; they are also used upon platinum-sensitive relapse. HRD in ovarian cancer is primarily assessed through BRCA genes mutations and genomic scar scores, which are key biomarkers forecasting PARPi benefit. However, the role of BRCA1 promoter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40775791
DOI: 10.1186/s13148-025-01917-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1 promoter methylation predicts PARPi response in ovarian cancer: insights from the KOMET studyPMID 40775791Read ↗

Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian CancerSemantic proximity Read ↗

Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity Read ↗

Clinical utility of HRR gene methylation for predicting PARPi sensitivity in HGSOC patientsSemantic proximity Read ↗

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.Semantic proximity Read ↗

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.Semantic proximity Read ↗

GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profilesSemantic proximity Read ↗

A novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study.Semantic proximity Read ↗

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencingSemantic proximity Read ↗

Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cellsSemantic proximity Read ↗

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.Semantic proximity Read ↗

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaSemantic proximity Read ↗

BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.